FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/18/2022
Back to search
Official data from USPTO
BRIGHT PEAK
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BRIGHT PEAK
ST13
US500000079285070Class
5, 42
Filing
79285070
Registration
6610085
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
07/18/2022
Trademark type
Word
Nice classes
5, 42
Filing date
03/25/2020
Registration date
01/11/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/11/2022
Last transaction
01/11/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
LAM, HAI-LY HUYNH
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Bright Peak Therapeutics AG
Representatives
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment and prevention of cancerautoimmune diseasesinfectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organsendocrine diseasesnutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemeye and adnexaear and mastoid process disordersdiseases of the circulatory systemrespiratory systemdigestive systemskin and subcutaneous tissue disordersdiseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemdisorders and abnormalities relating to pregnancy and childbirthcertain conditions originating in the puerperium and perinatal periodscongenital malformations and deformationschromosomal abnormalities; medical and veterinary preparationsrecombinant or chemically synthesized and optimized proteins; preparations for destroying vermin; fungicidesherbicides; biotechnological preparationsrecombinant or chemically synthesized and optimized proteins for medical use; enzymes for medical use; enzymes for veterinary use; biological and chemical reagents for medical or veterinary use; amino acids for medical use; amino acids for veterinary use; peptides for medical or veterinary usefor the treatment of cancerautoimmune diseasesinfectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organsendocrine diseasesnutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemeye and adnexaear and mastoid process disordersdiseases of the circulatory systemrespiratory systemdigestive systemskin and subcutaneous tissue disordersdiseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemdisorders and abnormalities relating to pregnancy and childbirthcertain conditions originating in the puerperium and perinatal periodscongenital malformations and deformationschromosomal abnormalities; proteins for medical or veterinary userecombinant or chemically synthesized and optimized proteins for detection and treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersautoimmune diseasesinfectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organsnutritional diseasesmental and behavioral disordersdiseases of the nervous systemeye and adnexaear and mastoid process disordersdiseases of the circulatory system and digestive systemskin and subcutaneous tissue disordersdiseases of the musculoskeletal system and connective tissuedisorders and abnormalities relating to pregnancy and childbirthcertain conditions originating in the puerperium and perinatal periodscongenital malformations and deformationschromosomal abnormalities; pharmaceutical preparations for cancer treatment; biopharmaceutical preparations for cancer treatment; pharmaceutical compositions and preparations for cancer prevention and treatment; pharmaceutical preparations for treatment of autoimmune and inflammatory diseases; pharmaceutical preparations for treatment of skin diseases; pharmaceutical preparations for treatment of neurodegenerativemetabolic and ophthalmological diseases
Class 42
Scientific and technological servicesscientific researchscientific analysisscientific testing in the field of biotechnology and new product research and design services relating thereto; research and development in the field of biotechnology; consulting services in the field of biotechnology; scientific research services in the field of proteinspeptides and antibodiesscientific advice relating thereto; scientific research services for medical purposes in the field of cancer and autoimmune diseases and scientific advice relating thereto
Publications
History of USPTO decisions and trademark events.
42 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/23/2022
FIMP
FINAL DISPOSITION PROCESSED
06/22/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/11/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/11/2022
GPNX
NOTIFICATION PROCESSED BY IB
11/04/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/03/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/26/2021
PUBO
PUBLISHED FOR OPPOSITION
10/26/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/13/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/13/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/06/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/06/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/06/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/17/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/17/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
08/24/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/24/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
08/24/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/24/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/29/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/29/2021
ALIE
ASSIGNED TO LIE
07/27/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/22/2021
EXPI
EX PARTE APPEAL-INSTITUTED
07/22/2021
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
07/22/2021
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
07/22/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/26/2021
GNFR
FINAL REFUSAL E-MAILED
01/26/2021
CNFR
FINAL REFUSAL WRITTEN
01/26/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/05/2021
RFNT
REFUSAL PROCESSED BY IB
08/07/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/23/2020
RFRR
REFUSAL PROCESSED BY MPU
07/23/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/18/2020
CNRT
NON-FINAL ACTION WRITTEN
06/17/2020
DOCK
ASSIGNED TO EXAMINER
06/16/2020
MAFR
APPLICATION FILING RECEIPT MAILED
05/12/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/08/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/07/2020
Continuous trademark protection
Get notified about every new filing that threatens BRIGHT PEAK or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.